NexImmune (NEXI) Stock Price, News & Analysis

Company Overview

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: $0.00 to $0.10
• 52-Week Range: $0.00 to $1.34
• Volume: N/A
• Average Volume: 6,303 shs
• Market Capitalization: $279.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NexImmune Stock Analysis - MarketRank™

NexImmune scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NexImmune.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NexImmune is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NexImmune has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.27% of the outstanding shares of NexImmune have been sold short.

Short Interest Ratio / Days to Cover

NexImmune has a short interest ratio ("days to cover") of 37, which indicates bearish sentiment.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NexImmune does not currently pay a dividend.

Dividend Growth

NexImmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.27% of the outstanding shares of NexImmune have been sold short.

Short Interest Ratio / Days to Cover

NexImmune has a short interest ratio ("days to cover") of 37, which indicates bearish sentiment.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for NexImmune this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NexImmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.90% of the stock of NexImmune is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.85% of the stock of NexImmune is held by institutions.

NEXI Stock Analysis - Frequently Asked Questions

How have NEXI shares performed this year?

NexImmune's stock was trading at $0.1151 at the beginning of 2025. Since then, NEXI shares have decreased by 99.8% and is now trading at $0.0002.

How were NexImmune's earnings last quarter?

NexImmune, Inc. (NASDAQ:NEXI) posted its quarterly earnings data on Friday, November, 12th. The company reported ($16.25) earnings per share for the quarter, topping the consensus estimate of ($16.75) by $0.50.

When did NexImmune's stock split?

NexImmune's stock reverse split on Thursday, October 19th 2023.The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did NexImmune IPO?

NexImmune (NEXI) raised $75 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO.

How do I buy shares of NexImmune?

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NexImmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEXI
• CIK: 1538210
• Web: www.neximmune.com
• Phone: 301-825-9810
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($18.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.34 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -534.32%
• Return on Assets: -213.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.66
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.32 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,395,000
• Free Float: 1,187,000
• Market Cap: $279.00
• Optionable: Not Optionable
• Beta: 1.94